Brokerage Firm Rating on Gilead Sciences (GILD)

Gilead Sciences (GILD) : The consensus on Gilead Sciences (GILD) based on 18 analyst recommendation on the company stock is 2.06, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 9 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Gilead Sciences (GILD) : The most positive equity analysts on Gilead Sciences (GILD) expects the shares to touch $133, whereas, the least positive believes that the stock will trade at $93 in the short term. The company is covered by 13 Wall Street Brokerage Firms. The average price target for shares are $111.31 with an expected fluctuation of $11.23 from the mean.


For the current week, the company shares have a recommendation consensus of Buy. Gilead Sciences (NASDAQ:GILD): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $79.15 and $78.80 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $79.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $79.57, notching a gain of 0.85% for the day. The total traded volume was 8,454,708 . The stock had closed at $78.90 on the previous day.

In a related news,The director officer (President and CEO) of Gilead Sciences Inc, Milligan John F sold 70,000 shares at $70.94 on August 1, 2016. The Insider selling transaction had a total value worth of $4,965,800. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.